TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9800052
Drug: Diltiazem CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem CR (90-120 mg) twice daily
Study: 8849215
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg once daily for 3 days)
Study: 7008293
Drug: Adjunctive antithymocyte
Normalized name: antithymocyte immunoglobulin (rabbit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antithymocyte globulin (ATG) therapy
Study: 7022879
Drug: Standard antirejection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antirejection treatment (SAT) of steroid pulsing and local irradiation
Study: 25546369
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution fasting (50mg)
Study: 25546369
Drug: Tablet fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet fasting (50mg)
Study: 25546369
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution fed (50mg)
Study: 25546369
Drug: Tablet fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet fed (50mg)
Study: 16267767
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment (early treatment group, n=64)
Study: 16267767
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (n=66)
Study: 8543715
Drug: EMDR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR treatment (3 sessions of 90 minutes each)
Study: 2102432
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Ibuprofen administered directly postoperatively (2nd administration after 6 hours)
Study: 2102432
Drug: Ibuprofen taken
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen taken as required
Study: 25833980
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) 20 g/d
Study: 21946544
Drug: Primary open-angle
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary open-angle glaucoma group with ET-1 level of 3.27±1.25 pg/mL
Study: 21946544
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with ET-1 level of 1.53±1.49 pg/mL
Study: 22315765
Drug: Ketamine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 6 mg kg(‐1)
Study: 22315765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ketamine 2.5 mg kg(‐1) and midazolam 0.25 mg kg(‐1)
Study: 19700035
Drug: Chapatis containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chapatis containing 4 g beta-glucan
Study: 19700035
Drug: Control chapatis
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control chapatis (0 g beta-glucan)
Study: 17122236
Drug: Single Shot
Normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Shot Spinal (SSS) with 2 mL of 0.5% hyperbaric bupivacaine
Study: 17122236
Drug: Combined Spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Spinal Epidural (CSE) with equivalent dose of hyperbaric bupivacaine
Study: 9727573
Drug: ZDV-3TC (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV-3TC (200 mg three times daily and 150 mg twice daily)
Study: 9727573
Drug: d4T-3TC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: d4T-3TC (40 mg and 150 mg, both twice daily)
Study: 9727573
Drug: Indinavir added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir added to both groups if plasma HIV RNA level at week 8 or thereafter was > 500 copies/ml
Study: 26123989
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine supplementation (10 g/day for 3 or 6 months)
Study: 26123989
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of L-arginine (0.5 g Arg/kg bodyweight for 30 min)
Study: 23616509
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (rich in daidzein, 60%) providing 94 mg isoflavones daily for 8 weeks
Study: 9130215
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment according to ASAM criteria
Study: 9130215
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient treatment according to ASAM criteria
Study: 9130215
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient treatment for alcohol patients who met ASAM criteria
Study: 21521545
Drug: LcS-fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LcS-fermented milk administered (n 39)
Study: 21521545
Drug: Non-administered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administered group (n 38)
Study: 21521545
Drug: LcS-fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LcS-fermented milk administered (n 10)
Study: 18356827
Drug: Catechin group
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin group (576 mg catechins per day)
Study: 18356827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (75 mg catechins per day)
Study: 16485702
Drug: Injection over
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection over longer times (5, 10, 15, or 20 sec)
Study: 12399900
Drug: Gastroenterology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroenterology treatment for patients with positive endoscopy findings
Study: 10720164
Drug: Rye bread
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye bread (20% of daily energy)
Study: 10720164
Drug: Wheat bread
Normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES WHEAT BREAD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bread (20% of daily energy)
Study: 8604444
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (sotalol or amiodarone)
Study: 12584835
Drug: Si' an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Si' an capsule combined Enalapril
Study: 10359467
Drug: Cortisol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol treatment (40 mg/d)
Study: 10359467
Drug: Cortisol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol treatment (160 mg/d)
Study: 7481854
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paclitaxel and doxorubicin
Study: 14521803
Drug: Single-agent paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent paclitaxel
Study: 19045968
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive therapy (CT)
Study: 28629905
Drug: Continuing antirheumatic
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing antirheumatic drug therapy
Study: 28629905
Drug: Withholding antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding antirheumatic drug therapy
Study: 28629905
Drug: Restarting antirheumatic
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Restarting antirheumatic medications post-surgery
Study: 24385407
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (100-300 mg/day)
Study: 19387336
Drug: Interactive Spaced
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interactive Spaced Education (ISE) on staghorn calculi, infertility, and antibiotic use (SIA)
Study: 17322151
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 to 160 mg once or twice daily)
Study: 26427036
Drug: Probiotic tablet
Normalized name: Acidophilus Probiotic Tablet
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic tablet containing Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145, used twice a day for 12 weeks
Study: 20533245
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) supplementation (159 mg/day total catechins)
Study: 18835479
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) with integrated emotion-regulation training
Study: 15865915
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT)
Study: 16633780
Drug: Target blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target blood propofol concentration of 6 microg x ml(‐1) (group 2)
Study: 11213884
Drug: Rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 2 mg twice daily
Study: 15089784
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg twice daily
Study: 10768088
Drug: Rosiglitazone 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 6 mg twice daily
Study: 11213884
Drug: Rosiglitazone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (all doses)
Study: 8101583
Drug: Intra-articular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular naloxone (0.04 mg)
Study: 8101583
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (0.04 mg)
Study: 24444428
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and laser treatment (810 nm diode laser using the 'hot tip' technique at ∼ 760 °C)
Study: 24444428
Drug: SRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP treatment alone
Study: 18240282
Drug: VSL#3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 (2 sachets once daily for 12 months)
Study: 15731606
Drug: Intrathecal levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal levobupivacaine and ropivacaine at doses of 2.5 mg or greater
Study: 797067
Drug: Xenon-arc photocoagulation
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon-arc photocoagulation treatment
Study: 24240315
Drug: Deep neuromuscular
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular block (post-tetanic count 1-2) using high-dose rocuronium
Study: 16154486
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg once daily for 8 weeks
Study: 16154486
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg once daily for 8 weeks
Study: 2576203
Drug: Transdermal mepindolol
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal mepindolol (BIO TSD)
Study: 58197
Drug: 3000 units
Normalized name: lactase 3000 units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 units of vitamin D2 in a capsule weekly
Study: 31059177
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg twice daily)
Study: 21608215
Drug: Bushen Qiangdu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Qiangdu Recipe (BSQDR), one dose daily, taken in two portions (morning and evening) for six months.
Study: 17082466
Drug: Seizure free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seizure free (SF) group, treated with 0 to 3 antiepileptic drugs (AEDs)
Study: 10393137
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet (502 +/‐ 99 mg)
Study: 2071884
Drug: Temazepam capsule
Normalized name: Temazepam Capsules
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temazepam capsule (20 mg)
Study: 12124949
Drug: IntraCoil stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IntraCoil stent treatment
Study: 7486100
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg i.v. bolus followed by continuous infusion of 5 mg/h for 24 h
Study: 17532826
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (200,000 IU single dose)
Study: 12240794
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg CONCERTA (methylphenidate HCI) after a high-fat breakfast
Study: 12240794
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg CONCERTA (methylphenidate HCI) after an overnight fast
Study: 12240794
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ADDERALL XR (mixed amphetamine salts) after an overnight fast
Study: 8673477
Drug: rIFN‐gamma therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma therapy
Study: 10677386
Drug: C-peptide infusion
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide infusion
Study: 21731866
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day
Study: 7810176
Drug: Tryptophan supplemented
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan supplemented diet (standard diet + 1.5 g tryptophan)
Study: 23129048
Drug: JTK-853 (800,
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTK-853 (800, 1,200, or 1,600 mg twice daily or 1,200 mg three times daily)
Study: 18929284
Drug: Dexmedetomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (bolus dose of 1 microg kg(‐1) and maintenance of 0.7 microg kg(‐1) hour(‐1))
Study: 16470820
Drug: Megestrol 160
Normalized name: megestrol acetate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol 160 mg
Study: 11604980
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (30 minutes)
Study: 10433305
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy (intracranial temperature 34 degrees C) for 48 hours followed by rewarming at 1 degree C per day for 3 days
Study: 10433305
Drug: Normothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia therapy (intracranial temperature 37 degrees C) for 5 days
Study: 10433305
Drug: Normothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia therapy
Study: 2720131
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered ibuprofen solution
Study: 17515464
Drug: BNP >
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP > or = 550 pg/mL
Study: 17515464
Drug: BNP <
Normalized name: Nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP < 550 pg/mL
Study: 17515464
Drug: BNP >
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP > or = 550 pg/mL in patients who underwent valve replacement
Study: 17515464
Drug: BNP <
Normalized name: Nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP < 550 pg/mL in patients who underwent valve replacement
Study: 15155424
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone acetate mixed with a short acting local anaesthetic
Study: 2955688
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy within 2 hours of symptom onset
Study: 2955688
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy within 3 hours of symptom onset
Study: 20435181
Drug: Aspirin <150/180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin <150/180 pills/y
Study: 20435181
Drug: Aspirin >150/180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin >150/180 pills/y and NSAID users <60 days/y
Study: 20435181
Drug: Aspirin <150/180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin <150/180 pills/y and NSAID users >60 days/y
Study: 15191344
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bisoprolol given orally
Study: 3103414
Drug: Submaintenance infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submaintenance infusion (1.02 +/- 0.04 times fasting M, n = 6)
Study: 3103414
Drug: Maintenance infusion
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance infusion (1.39 +/- 0.01 times fasting M, n = 20)
Study: 17853755
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment group (Yingxiang (LI 20), Shangyingxiang (EX‐HN 8), Yintang (EX‐HN 3), Hegu (LI 4), Fengchi (GB 20), Dazhui (GV 14), Feishu (BL 13))
Study: 17853755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group II (oral administration of Biyankang tablets, 4 tablets each time, thrice each day)
Study: 11772242
Drug: Ertapenem at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem at 2 mg/kg
Study: 11772242
Drug: Imipenem at
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem at 2 mg/kg
Study: 9389782
Drug: Peroral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral oestrogen (2 mg oestradiol valerate tablets)
Study: 18435668
Drug: Sulphonylurea therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea therapy
Study: 24996592
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise treatment (both experiments)
Study: 22814420
Drug: Aspirin challenge
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin challenge (placebo-controlled)
Study: 19031508
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/day with alfacalcidol 1 microg/day
Study: 16000354
Drug: Anagrelide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide plus low-dose aspirin
Study: 12197051
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with another vaccine
Study: 10425010
Drug: Titration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration group (n = 20) received protamine doses based on heparin concentration measured by the Hepcon system.
Study: 10425010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 14) received a fixed dose of protamine (3 mg/kg).
Study: 10425010
Drug: Titration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration group (n = 20)
Study: 7478713
Drug: MOR-L (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR-L (11 min)
Study: 7478713
Drug: FEN-L (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEN-L (8 min)
Study: 7478713
Drug: Lockout intervals
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lockout intervals (L and S)
Study: 1904749
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen 200 mg
Study: 1904749
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen 800 mg
Study: 21128873
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and Sertraline
Study: 17911873
Drug: Guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided dosing within a computerized provider order entry (CPOE) system
Study: 17911873
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no guided dosing)
Study: 17911873
Drug: Guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided dosing within a CPOE system